HGEN - Seres Jumps On Data And Other News: The Good Bad And Ugly Of Biopharma
Seres Therapeutics stock jumps on positive topline data
Seres Therapeutics Inc. (MCRB) stock recorded swift boost as the company announced positive data from its Phase 3 ECOSPOR III study. The company reported that the drug candidate was able to bring about statistically significant changes. The efficacy results also surpassed the previously set statistical threshold.
The ECOSPOR III study is a multicenter, randomized, placebo-controlled study. It involved 182 patients suffering from multiply recurrent CDI, which were randomized 1:1 to receive either SER-109 or placebo, after standard of care antibiotic treatment. They were given SER-109,